Private equity has spent years consolidating dental practices, dermatology clinics, and orthopedic groups. Now it has found a quieter target: oral and maxillofacial surgery. Regional oral surgery groups – often two to ten surgeons operating under a single brand – are selling to PE-backed rollup platforms at a pace that is starting to reshape how this specialty delivers care.
Why Oral Surgery Became PE’s Favorite Specialty
Oral surgery sits in a financially attractive middle ground. It is surgical, which means higher per-procedure revenue than general dentistry. It is also mostly elective or semi-elective – wisdom teeth extractions, implant placements, jaw corrections – which makes scheduling predictable and cash flow relatively stable. Unlike hospital-based surgery, most oral surgery is performed in office-based settings, which means lower overhead and no health system bureaucracy to navigate. That combination is almost tailor-made for a rollup model.
The specialty also has a referral dynamic that works in PE’s favor. General dentists send patients to oral surgeons consistently and repeatedly. A well-run platform that controls multiple oral surgery locations in a single metro area can quietly dominate that referral flow, making it difficult for independent practices to compete for the same patients. Once a rollup secures relationships with enough referring dentists, independent surgeons in that market face real headwinds.
There is also a supply constraint working in PE’s favor. Oral and maxillofacial surgery residencies are small programs with competitive entry, which means the pipeline of new surgeons entering practice each year is relatively narrow. That limits how quickly independent competition can fill any gaps a rollup creates, and it gives existing practice owners more leverage during negotiations – at least at the front end of a deal.
Several PE platforms that built their reputations rolling up general dental service organizations have now pivoted toward specialty dentistry, and oral surgery is the most active segment. The economics of specialty over general dentistry are straightforward: higher average revenue per patient, lower volume pressure, and a more defensible market position once scale is achieved.
What the Deals Actually Look Like
Most oral surgery acquisitions follow a structure that has become standard across PE rollups in healthcare specialties: a founding group sells a majority stake to the platform, receives a mix of cash and equity in the larger entity, and the original surgeons stay on as clinical partners under an employment or professional services agreement. The founding partners typically retain a minority equity stake, betting that a future sale of the larger platform – usually within five to seven years – will generate a second payout that exceeds the first.
That second bite of the apple is the pitch that convinces many practice owners to sell. A surgeon running a profitable four-person group in a mid-sized market might receive a strong multiple on EBITDA at the initial sale, but the real incentive is the rollup equity. If the platform grows from twenty locations to eighty locations and sells to a larger strategic buyer or a second PE fund at a higher multiple, the retained equity can be worth significantly more than the original transaction. It is a compelling financial argument, and it is the reason many practice owners who once swore they would never sell end up signing.
The operational reality after a sale varies considerably by platform. Some PE buyers genuinely invest in infrastructure – centralized billing, credentialing support, group purchasing, marketing – that reduces administrative burden on clinicians. Others cut overhead aggressively, consolidate locations, and push volume targets that create friction with the surgeons who signed expecting autonomy. The difference often comes down to which PE firm is involved and what their hold period strategy looks like.
Pricing multiples in oral surgery have remained high relative to other healthcare sectors, even as deal activity in some other specialties has cooled. A well-run oral surgery group with strong EBITDA margins, a loyal referral base, and clean financials can command a multiple that makes the transaction feel like an early retirement option for founding partners in their fifties. For surgeons who built their practice over twenty or thirty years, the numbers can be difficult to walk away from.
Not every surgeon is selling, and not every group that explores a deal closes one. Some practice owners go through the entire diligence process – often a six-to-twelve-month commitment – and walk away when they see what operational control they would actually be giving up. The gap between what PE platforms promise in an introductory meeting and what the definitive agreements actually say can be substantial, and the surgeons who hire experienced healthcare transaction counsel before signing tend to end up in better positions than those who do not.
What Independent Oral Surgeons Face Going Forward
Independent oral surgery practices in markets where a rollup has established a foothold are already feeling the competitive pressure. Rollup platforms can invest in patient experience, digital marketing, and extended scheduling in ways that a two-person independent practice simply cannot match at the same cost. Referral relationships that independent surgeons spent a decade building can shift when a PE-backed competitor opens a sleek new facility three miles away and actively courts the same general dentist offices. The economics of staying independent get harder, which is precisely the dynamic that drives the next wave of sellers.
The longer-term question – one that regulators are beginning to ask more carefully – is whether consolidation in a specialty with limited surgeon supply leads to pricing pressure on patients and payors. Oral surgery already sits in a gray zone between dental and medical insurance coverage, which means patients often carry significant out-of-pocket exposure. A market where one platform controls the majority of oral surgery capacity has fewer natural checks on what it can charge, especially for procedures that are not easily deferred. That is the tension that does not resolve itself quietly.
